Recent Quotes (30 days)

You have no recent quotes
chg | %

DBV Technologies SA - ADR  

(Public, NASDAQ:DBVT)   Watch this stock  
Find more results for DBVT
25.03
-0.83 (-3.21%)
After Hours: 25.02 -0.01 (-0.04%)
Feb 20, 4:11PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.80 - 26.26
52 week 20.08 - 50.57
Open 23.85
Vol / Avg. 1.49M/305,187.00
Mkt cap 1.28B
P/E     -
Div/yield     -
EPS     -
Shares 24.67M
Beta 1.03
Inst. own     -
Apr 27, 2018
Q1 2018 DBV Technologies SA Corporate Sales Release - 3:00AM EDT - Add to calendar
Mar 14, 2018
Full Year 2017 DBV Technologies SA Earnings Release - 4:00AM EDT - Add to calendar
Feb 22, 2018
DBV Technologies SA at RBC Capital Markets Healthcare Conference - 11:00AM EST - Add to calendar
Feb 20, 2018
Full Year 2017 DBV Technologies SA Corporate Sales Release
Feb 14, 2018
DBV Technologies SA at Leerink Partners Global Healthcare Conference
Jan 10, 2018
DBV Technologies SA at JPMorgan Healthcare Conference - Webcast
Dec 6, 2017
DBV Technologies SA at Citi Global Healthcare Conference
More events from DailyFinance »    

Address

177-181 avenue Pierre Brossolette
MONTROUGE, 92120
France
+33-1-55427878 (Phone)
+33-1-43261083 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Officers and directors

Pierre-Henri Benhamou Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
David Schilansky Chief Operating Officer
Bio & Compensation  - Reuters
Hugh A. Sampson M.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Lucie Mondoulet Director of Research
Bio & Compensation  - Reuters
Nathalie Donne Director of Corporate Communication & Business Development
Bio & Compensation  - Reuters
Veronique Foutel Director of Strategic Marketing
Age: 46
Bio & Compensation  - Reuters
Wence Agbotounou Chief Clinical Trial Officer
Bio & Compensation  - Reuters
Bertrand Dupont Industrial Director
Bio & Compensation  - Reuters
Pascale Ehouarn Industrial Development and Production Director
Bio & Compensation  - Reuters
Laurent Martin Director of Regulatory Affairs
Bio & Compensation  - Reuters